Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells

Oncotarget

Volumn 5, Issue 19, 2014, Pages 8924-8936

  Yi, Lan ^a,b   Sun, Yvonne ^a,b   Levine, Arnold ^a,b,c  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

Decitabine; DNA methylation inhibitor; EGCG; FCDR; P53; RG108; Zebularine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 FLUORO 20 DEOXYCYTIDINE; DEOXYCYTIDINE; EPIGALLOCATECHIN GALLATE; N PHTHALOYLTRYPTOPHAN; PROTEIN P53; UNCLASSIFIED DRUG; ZEBULARINE; ANTINEOPLASTIC AGENT; AZACITIDINE; CATECHIN; CYTIDINE; DECITABINE; PHTHALIMIDE DERIVATIVE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE; TRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EMBRYO; EPIGENETICS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; KNOCKOUT MOUSE; LUNG NEOPLASMS; METABOLISM; MUTATION; TUMOR CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; AZACITIDINE; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYTIDINE; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; NEOPLASM TRANSPLANTATION; PHTHALIMIDES; TRYPTOPHAN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84910049319     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2441     Document Type: Article

References (25)

1. Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman J, Lee P, WilsonC, Lander E and Jaenisch R. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat Genet. 2001; 27(1):31-39.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-872.
3. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG and HochedlingerK. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009; 460(7259): 1145-1148.
4. Marion RM, Strati K, Li H, Murga M, Blanco R, OrtegaS, Fernandez-Capetillo O, Serrano M and Blasco MA. Ap53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009; 460(7259):1149-1153.
5. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA and Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009; 460(7259):1136-1139.
6. Kawamura T, Suzuki J, Wang YV, Menendez S, MoreraLB, Raya A, Wahl GM and Izpisua Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature. 2009; 460(7259):1140-1144.
7. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K and Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009; 460(7259):1132-1135.
8. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L and Gil J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009; 23(18):2134-2139.
9. Yi L, Lu C, Hu W, Sun Y and Levine AJ. Multiple roles of p53-related pathways in somatic cell reprogramming andstem cell differentiation. Cancer Res. 2012; 72(21):5635-5645.
10. Lutzker SG and Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med. 1996; 2(7):804-810.
11. Mizuno H, Spike BT, Wahl GM and Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci U S A. 2010; 107(52):22745-22750.
12. Ting DT, Lipson D, Paul S, Brannigan BW, AkhavanfardS, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S and Haber DA. Aberrant overexpression of satellite repeats in pancreaticand other epithelial cancers. Science. 2011; 331(6017):593-596.
13. Leonova KI, Brodsky L, Lipchick B, Pal M, NovototskayaL, Chenchik AA, Sen GC, Komarova EA and GudkovAV. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A. 2013; 110(1):E89-98.
14. Pearson BJ and Sanchez Alvarado A. A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages. Development. 2010; 137(2):213-221.
15. Yun MH, Gates PB and Brockes JP. Regulation of p53 is critical for vertebrate limb regeneration. Proc Natl Acad Sci U S A. 2013; 110(43):17392-17397.
16. Harvey DM and Levine AJ. p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 1991; 5(12B):2375-2385.
17. Feinberg AP and Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004; 4(2):143-153.
18. Zheng YG, Wu J, Chen Z and Goodman M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev. 2008; 28(5):645-687.
19. Nieto M, Samper E, Fraga MF, Gonzalez de Buitrago G, Esteller M and Serrano M. The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine. Oncogene. 2004; 23(3):735-743.
20. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK and Lozano G. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A. 2000; 97(8):4174-4179.
21. Markert EK, Mizuno H, Vazquez A and Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A. 2011; 108(52):21276-21281.
22. Iannello A, Thompson TW, Ardolino M, Lowe SW and Raulet DH. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med. 2013; 210(10):2057-2069.
23. June C, Rosenberg SA, Sadelain M and Weber JS. T-cell therapy at the threshold. Nat Biotechnol. 2012; 30(7): 611-614.
24. Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, YenRW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, Stearns V, Pardoll DM, Davidson N, Jones PA, Slamon DJ and Baylin SB. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014; 5(3):587-598.
25. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR and Tykodi SS. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013; 4(11):2067-2079.